Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | UBE2N | P61088 | 1/20 | 0.51 |
| ▸ | ELANE | P08246 | 3/20 | 0.50 |
| ▸ | BCHE | P06276 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29721165 | 1.00 | SLC2A1 (0.59) | SLC2A1LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL11320083 | 0.91 | SLC2A1 (0.56) | SLC2A1LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL10796837 | 0.91 | KDM4E (0.60) | SLC2A1LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL30791321 | 0.90 | SLC2A1 (0.58) | SLC2A1LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL21633635 | 0.90 | SLC2A1 (0.58) | SLC2A1LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL6881536 | 0.89 | BCHE (0.63) | CYP1A2KMT2ABCHEKDM4EHPGD | |
| SCHEMBL31444153 | 0.89 | BCHE (0.63) | LMNAHDAC6KMT2AELANEBCHE | |
| SCHEMBL6035592 | 0.89 | BCHE (0.63) | LMNAHDAC6KMT2AELANEBCHE | |
| SCHEMBL21633577 | 0.88 | C5AR1 (0.58) | SLC2A1LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL10801528 | 0.88 | C5AR1 (0.52) | SLC2A1LMNACYP1A2PTGS1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3828163-B1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING PROTEINOPATHIES COMPRISING SAME | AUTOTAC INC (KR) | 2026-05-20 | — | — | EP | disclosed |
| EP-3828164-B1 | NOVEL AUTOPHAGY-TARGETING CHIMERA (AUTOTAC) COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING DISEASES THROUGH TARGET PROTEIN DEGRADATION COMPRISING SAME | AUTOTAC INC (KR) | 2025-10-29 | — | — | EP | disclosed |
| US-12427346-B2 | P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same | AUTOTAC INC. (KR) | 2025-09-30 | — | — | US | disclosed |
| US-12383624-B2 | Cargo delivery system and composition comprising the same | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-08-12 | — | — | US | disclosed |
| EP-3828162-B1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING PROTEINOPATHIES COMPRISING THE SAME | AUTOTAC INC (KR) | 2025-07-09 | — | — | EP | disclosed |
| US-12129218-B2 | AUTOTAC chimeric compound, and composition for preventing, ameliorating or treating diseases through targeted protein degradation comprising the same | AUTOTAC INC. (KR) | 2024-10-29 | — | — | US | disclosed |
| EP-4373813-A1 | COMPOUNDS AND METHODS FOR DETECTION OF SUPEROXIDE | PROMEGA CORPORATION (US) | 2024-05-29 | — | — | EP | disclosed |
| US-11981618-B2 | P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same | AUTOTAC INC. (KR) | 2024-05-14 | — | — | US | disclosed |
| CN-112672993-B | Novel AUTOTAC chimeric compounds and compositions comprising same for preventing, ameliorating or treating diseases by targeted protein degradation | 奧土择破利悟株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-11802114-B2 | Compounds and methods for detection of superoxide | PROMEGA CORPORATION (US) | 2023-10-31 | — | — | US | disclosed |
| US-5726165-A | HYPOGLYCEMIC AGENTS; DIETETICS; GASTROINTESTINAL DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-03-10 | — | — | US | disclosed |
| EP-0778267-A1 | SULFONAMIDE DERIVATIVES AND INSECTICIDE, MITICIDE AND NEMATICIDE CONTAINING THE SAME | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1997-06-11 | — | — | EP | disclosed |
| EP-0772585-A1 | ARYLOXY AND ARYLTHIOPROPANOLAMINE DERIVATIVES USEFUL AS BETA 3-ADRENORECEPTOR AGONISTS AND ANTAGONISTS OF THE BETA 1 AND BETA 2-ADRENORECEPTORS AND PHARMACEUTICAL COMPOSITION THEREOF | SMITHKLINE BEECHAM PLC (GB) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996004234-A1 | ARYLOXY ANDARYCTHIO PROPANOLAMINE DERIVATIVES USEFUL AS B3-ADRENORECEPTOR AGONISTS AND ANTAGONS OF THE B1 AND B2 ADRENORECEPTORS AND PHARMACEUTICAL COMPOSITION THEREOF | SMITHKLINE BEECHAM PLC (GB) | 1996-02-15 | — | — | WO | disclosed |
| WO-1996004233-A1 | ARYLOXY AND ARYLTHIOPROPANOLAMINE DERIVATIVES USEFUL AS BETA 3-ADRENORECEPTOR AGONISTS AND ANTAGONISTS OF THE BETA 1 AND BETA 2-ADRENORECEPTORS AND PHARMACEUTICAL COMPOSITION THEREOF | SMITHKLINE BEECHAM PLC (GB) | 1996-02-15 | — | — | WO | disclosed |
| EP-0346367-A1 | ARYL- AND ARYLOXY-SUBSTITUTED TERT.-ALKYLENAMINES, PROCESS FOR THEIR MANUFACTURE AND THEIR USE IN PHARMACY | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-12-20 | — | — | EP | disclosed |
| WO-1988006580-A1 | ARYL- AND ARYLOXY-SUBSTITUTED TERT.-ALKYLENAMINES, PROCESS FOR THEIR MANUFACTURE AND THEIR USE IN PHARMACY | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-09-07 | — | — | WO | disclosed |
| US-4695585-A | 7-oxabicyclo(2.2.1)heptane analogs useful as inhibitors of 5-lipoxygenase and cyclooxygenase | E. R. SQUIBB & SONS, INC. (US) | 1987-09-22 | — | — | US | disclosed |
| US-4013777-A | BRONCHODILATORS | SMITHKLINE CORPORATION (US) | 1977-03-22 | — | — | US | disclosed |
| US-3933837-A | 3,4-Methylenedioxyphenoxy-alkyl diketones and keto-esters | STERLING DRUG INC. (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12427346-B2 | P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same | SQSTM1, ATG7, BECN1 | SLC2A1 1584/4885LMNA 364/4885CYP1A2 4604/4885 |
| US-12129218-B2 | AUTOTAC chimeric compound, and composition for preventing, ameliorating or treating diseases through targeted protein degradation comprising the same | ATG7, SQSTM1, CTSA | SLC2A1 522/4885LMNA 601/4885CYP1A2 4395/4885 |
| US-12383624-B2 | Cargo delivery system and composition comprising the same | ATG7, SQSTM1, BECN1 | SLC2A1 397/4885LMNA 1430/4885CYP1A2 4798/4885 |
| US-11802114-B2 | Compounds and methods for detection of superoxide | SOD1, GPX4, SOD3 | SLC2A1 1703/4885LMNA 1365/4885CYP1A2 334/4885 |
| US-11981618-B2 | P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same | SQSTM1, ATG7, BECN1 | SLC2A1 1774/4885LMNA 250/4885CYP1A2 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.